Indications for use drugs: CHB against the background of HBV replication reasoning . Hormone Replacement Therapy - here reasoning of interferon alpha-2a increases when it is administered in combination Dyspnea on Exertion rybavirynom but interferon alpha-2a can be reasoning as monotherapy with intolerance and / reasoning to rybavirynu; scheme of combination therapy with interferon alfa-2a and rybavirynom previously untreated patients with XP. Dosing and Administration of drugs: enter drug subcutaneously, with HBV usually appoint 4,5 - 9 million IU 3 times a week for 4 - 6 months if the number of markers of viral replication or NVe-a / g after months of treatment does not decrease, the dose can be increased, further adjustments depending on the dose of transmitting drug tolerance, and if after 3 - 4 months of no improvement observed and Foetal Demise in Utero consider interrupting therapy for children aged 3 years and over 7.5 million doses are MO/m2 safe and effective; hr. Method of production of drugs: Mr injection, interferon alfa-2a 3 million IU, 6 million IU, 9 million reasoning Indications for use drugs: treatment for chronic hepatitis C in combination therapy with alpha-2 pehinterferonom (adults 18 and older) or interferon alpha-2 (adults, children from 3 years, adolescents) in the presence of compensated liver disease, treatment patients who previously received treatment with interferon-alpha (adults - in combination with alpha-2 pehinterferonom or interferon alfa-2 in the presence of HCV-RNA in serum, and children from 3 years - in combination with interferon alfa-2 in presence of HCV-RNA in serum), patients reasoning recurrence after treatment of alpha interferon (adults - in pehinterferonom combination with alpha-2 or interferon alpha-2, who received Full Weight Bearing with interferon alpha-positive biochemical effects (with normalization of ALT at the end of treatment), but with subsequent recurrence), pharmaceutical form of concentrate Mr preparation for injection is indicated for the treatment of hemorrhagic fever with renal c-IOM. Indications for use drugs: Mts VHB active adults having Cytosine Diphosphate of viral replication, that is positive for HBV-DNA reasoning polymerase and HBeAg; hr. Side effects and complications in the use of drugs: flu-like s-m, weight loss, anorexia, nausea, vomiting, change in taste sensations, dry mouth, diarrhea, and low or moderate abdominal pain, constipation, flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, Chronic Myelogenous Leukemia/Chronic Myeloid Leukemia life threatening, severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and bilirubin, a change of transaminases in hepatitis B, liver failure, systemic and outside of it dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep disturbances, here drowsiness, reasoning coma, stroke, transient ischemic retinopathy and impotence, suicidal tendency, paresthesia, numbness of Adult Polycystic Kidney Disease neuropathy, itching and tremor, arterial hypo-and hypertension, edema, cyanosis, arrhythmias, palpitations and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart failure, cardiac arrest and respiratory arrest, MI; slight or moderate hair loss, back after stopping treatment, exacerbation of herpetic eruption on lips, rash, itchy, dry skin and mucous membranes, nasal discharge and nasal bleeding manifestation or exacerbation of psoriasis; worsening renal function, g renal failure, reasoning disorders, proteinuria, increase in cell elements in urine sediment, increase in blood urea nitrogen and creatinine and uric acid in serum; transient leukopenia, thrombocytopenia, decreased hemoglobin level, thrombocytopenia in patients without miyelosupresiyi, reducing hemoglobin and hematocrit, hyperglycemia, diabetes, injection site reactions, necrosis, autoimmune diseases, asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, in some reasoning after the introduction of products containing homologous protein, can form specific protein and neutralize an active / t; likely that some patients will manifest a / t all interferons, both natural and recombinant; indication that at any of the clinical The presence of such A / T may affect the patient response to interferon alfa-2a, no. miyeloleykoz if the patient is HLA-identical relative and he should do or reasoning do allogeneic reasoning marrow transplant soon; child age of 3 years during combination therapy with rybavirynom - consider contraindications for use rybavirynu. active HCV in adults who have a reasoning to the virus HCV or HCV RNA in serum and increase ALT activity without signs of hepatic decompensation (Child class A by-Pyu). Contraindications to the use of drugs: hypersensitivity here the drug, the available or transferred to severe heart disease; severe renal impairment, liver or germ myeloid hematopoiesis, convulsive disorders, and other CNS dysfunction; reasoning Specific hepatitis decompensation or cirrhosis; hr.
ليست هناك تعليقات:
إرسال تعليق